Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Efzofitimod by ATyr Pharma for Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease): Likelihood of Approval
Efzofitimod is under clinical development by ATyr Pharma and currently in Phase II for Interstitial Lung Diseases (Diffuse Parenchymal Lung...
Efzofitimod by ATyr Pharma for Systemic Sclerosis (Scleroderma): Likelihood of Approval
Efzofitimod is under clinical development by ATyr Pharma and currently in Phase II for Systemic Sclerosis (Scleroderma). According to GlobalData,...
Efzofitimod by ATyr Pharma for Coronavirus Disease 2019 (COVID-19) Pneumonia: Likelihood of Approval
Efzofitimod is under clinical development by ATyr Pharma and currently in Phase II for Coronavirus Disease 2019 (COVID-19) Pneumonia. According...